Publications Scientifiques

[ Article ] A retrospective pharmacovigilance study of antiretroviral therapy in a pediatric setting in benin

Date de soumission: 23-02-2018
Année de Publication: 2017
Entité/Laboratoire Autres laboratoires
Document type : Article
Discipline(s) : Pharmacie, Pharmacologie & Toxicologie
Titre A retrospective pharmacovigilance study of antiretroviral therapy in a pediatric setting in benin
Auteurs ALLABI AUREL CONSTANT EUSTACHE [1], Gratien Sagbo [2], Ekanmian Giraud [3], Koumakpai-Adeoty Sikiratou [4], Ganfon Habib [5], Ganfon Habib [5], Sarfo Maame Anima A- [6],
Journal: Journal of Pharmacovigilance and Pharma-cotherapeutics
Catégorie Journal: Internationale
Impact factor: 0
Volume Journal: 2017
DOI: DOI: 10.29011/JPPT-113. 100113
Resume Objective: With the new WHO recommendations, the new eligibility criteria for antiretroviral therapy suggest an early start of treatment which causes a longer duration of exposure to antiretroviral therapy especially for children and newborns. It therefore appears essential due to the potential risks associated with the use of antiretroviral drugs, to promote the care of patients by looking out for adverse drug reactions to improve the safety of the treatment. Methods: We conducted a Pharmacovigilance retrospective study from January 2002 to July 2013. It included 237 HIV positive children on Antiretroviral Therapy (ART) who were monitored on the pediatric ward of the teaching hospital CNHU-HKM of Cotonou in Benin Republic. Results: Adverse events (AEs) accounted for 8.7% of the reason for change in ARV treatment and this was mainly due to the tri-therapy lamivudine + zidovudine + (nelfinavir or nevirapine) which was responsible for 62.5% of all cases. Most common AEs affected the skin and the digestive system: pruritus (28.89%), diarrhea (13.33%), and skin outbreak (11.11%). The incidence of AEs for the various combinations: lamivudine + zidovudine + efavirenz, lamivudine + zidovudine + nevirapine, lamivudine + stavudine + nevirapine and lamivudine + zidovudine + nelfinavir, were respectively 2.55, 3.19, 4.77 and11.54 cases for 1000 persons-month. Serious AEs accounted for11.11% of the cases and this was related to anemia and this was linked to the combination lamivudine + zidovudine + nelfinavir, and this was responsible for 4.4% cases of hospitalization. Serious AEs also included bone deformation imputed to lamivudine + zidovudine + nelfinavir and lamivudine + stavudine + nelfinavir and amyotrophy imputed to lamivudine + didanosine + nelfinavir. The mechanism of occurrence of the AEs was more pharmacological (47%) often with the combination oflamivudine +zidovudine + nelfinavir than immuno-allergic (44%) or chronic (9%). The average onset of adverse event was 9 months. Advanced age and serious immunological deficiency at the beginning of the tri-therapy and a concomitant antitubercular treatment as well as the seronegative status of the tutor favored the appearance of the AEs. Conclusion: Our results show that it is better to start early ART in order to reduce the occurrence of Adverse Drug Reactions. Active Pharmacovigilance should be implemented in pediatric settings in order to optimize the therapeutic monitoring of patients and prevent the occurrence of adverse drug reactions.
Mots clés Antiretroviral Therapy; Adverse Events; Children Pharmacovigilance
Pages 1 - 8
Fichier (PDF)

Publications par entité

  • Centre de Formation et de Recherche en matière de Population (CEFORP) (21)
  • Centre Interfacultaire de Formation et de Recherche en Environnement pour le Développement Durable (CIFRED) (43)
  • Chaire Internationale en Physique Mathématique et Applications (CIPMA-Chaire UNESCO) (45)
  • Ecole Doctorale Pluridisciplinaire <<Espaces, Culture et Développement>> (0)
  • Ecole Nationale d'Administration et de Magistrature (ENAM) (73)
  • Ecole Nationle d'Economie Appliquée et de Management (88)
  • Ecole Normale Supérieure (35)
  • Ecole Polytechnique d'Abomey-Calavi (EPAC) (1126)
  • Faculté de droit et de Science Politique (FADESP) (113)
  • Faculté des Lettres et Sciences Humaines (FLASH) (1378)
  • Faculté des Lettres, Langues, Arts et Communications (FLLAC) (0)
  • Faculté des Sciences Agronomiques (1943)
  • Faculté des Sciences de la Santé (FSS) (2334)
  • Faculté des Sciences Economiques et de Gestion (FASEG) (191)
  • Faculté des Sciences et Techniques (FAST) (1082)
  • Faculté des Sciences Humaines et Sociales (FASHS) (70)
  • Institut de Formation et de Recherche en Informatique (IFRI) (76)
  • Institut de Géographie de l'Aménagement du territoire et de l'Environnement (IGATE) (0)
  • Institut de Mathématiques et de Sciences Physiques (IMSP) (124)
  • Institut National de l'Eau (INE) (28)
  • Institut National des Métiers d'Art d'Archéologie et de la Culture (INMAAC) (11)
  • Institut National Médico Sanitaire ( INMeS) (0)
  • Institut Régional de Santé Publique (IRSP) (84)

Publications par sexe

  • Femme( 1400 )
  • Homme (